These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14507746)

  • 1. What is the cost of blindness?
    Meads C; Hyde C
    Br J Ophthalmol; 2003 Oct; 87(10):1201-4. PubMed ID: 14507746
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life and health economic assessments of age-related macular degeneration.
    Covert D; Berdeaux G; Mitchell J; Bradley C; Barnes R
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S20-5. PubMed ID: 17240252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N; Davis S; Brazier J
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration.
    Ke KM
    Eur J Health Econ; 2010 Dec; 11(6):525-31. PubMed ID: 19936811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Social costs of visual handicap and blindness. Rehabilitation resources for blind patients].
    Krumpaszky HG; Klauss V; Kloske G
    Klin Monbl Augenheilkd; 1992 Dec; 201(6):370-4. PubMed ID: 1287358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of blind rehabilitation for veterans with macular diseases in the Department of Veterans Affairs.
    Stroupe KT; Stelmack JA; Tang XC; Reda DJ; Moran D; Rinne S; Mancil R; Wei Y; Cummings R; Mancil G; Ellis N; Massof RW
    Ophthalmic Epidemiol; 2008; 15(2):84-91. PubMed ID: 18432491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for age-related macular degeneration.
    Wagle AM; Yeo TK; Au Eong KG
    Lancet; 2007 Oct; 370(9597):1481. PubMed ID: 17964347
    [No Abstract]   [Full Text] [Related]  

  • 9. 56,000 Ways? No way!
    Brown GC
    Curr Opin Ophthalmol; 2006 Jun; 17(3):219-22. PubMed ID: 16794432
    [No Abstract]   [Full Text] [Related]  

  • 10. The societal burden of blindness secondary to retinopathy of prematurity in Lima, Peru.
    Dave HB; Gordillo L; Yang Z; Zhang MS; Hubbard GB; Olsen TW
    Am J Ophthalmol; 2012 Oct; 154(4):750-5. PubMed ID: 22831839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related macular degeneration: legal vs total blindness.
    Pinsky N
    Can Fam Physician; 1997 May; 43():841. PubMed ID: 9154352
    [No Abstract]   [Full Text] [Related]  

  • 12. Does age-related macular degeneration (AMD) cause blindness?
    Johns Hopkins Med Lett Health After 50; 2000 Jul; 12(5):8. PubMed ID: 10879155
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic burden of blindness in India.
    Shamanna BR; Dandona L; Rao GN
    Indian J Ophthalmol; 1998 Sep; 46(3):169-72. PubMed ID: 10085631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Age related macular degeneration and subretinal neovessels. Primary cause of acquired blindness in adults in France].
    Coscas G
    Rev Prat; 1991 Nov; 41(23):2320-2. PubMed ID: 1792495
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of blindness caused by senile macular degeneration in Greenland.
    Rosenberg T
    Arctic Med Res; 1987 Oct; 46(2):64-70. PubMed ID: 3426774
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic blindness--macular dystrophies and retinitis pigmentosa.
    Greenberg J; Peters AL
    S Afr Med J; 1995 Jun; 85(6):492-3. PubMed ID: 7652623
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of blindness due to senile disciform macular degeneration.
    Bird AC
    Trans Ophthalmol Soc U K (1962); 1978; 98(2):303-4. PubMed ID: 286462
    [No Abstract]   [Full Text] [Related]  

  • 20. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP; Brown GC; Brown MM
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.